Path Forward for RAF Therapies: Inhibition of Monomers and Dimers

Robert L. Kortum; Deborah K. Morrison

doi:10.1016/j.ccell.2015.08.006

Path Forward for RAF Therapies: Inhibition of Monomers and Dimers

Robert L. Kortum, Deborah K. Morrison^*

^*Corresponding author for this work

Pharmacology and Molecular Therapeutics

Research output: Contribution to journal › Short survey › peer-review

15 Scopus citations

Abstract

Current BRAF inhibitors block signaling from monomeric BRAF^V600E, but not from oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric and dimeric RAF.

Original language	English
Pages (from-to)	279-281
Number of pages	3
Journal	Cancer Cell
Volume	28
Issue number	3
DOIs	https://doi.org/10.1016/j.ccell.2015.08.006
State	Published - 14 Sep 2015

Access to Document

10.1016/j.ccell.2015.08.006

Cite this

@article{9accb3aa1c5a457ea4f6abda915f3fd9,

title = "Path Forward for RAF Therapies: Inhibition of Monomers and Dimers",

abstract = "Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric and dimeric RAF.",

author = "Kortum, \{Robert L.\} and Morrison, \{Deborah K.\}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = sep,

day = "14",

doi = "10.1016/j.ccell.2015.08.006",

language = "English",

volume = "28",

pages = "279--281",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Path Forward for RAF Therapies

T2 - Inhibition of Monomers and Dimers

AU - Kortum, Robert L.

AU - Morrison, Deborah K.

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric and dimeric RAF.

AB - Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric and dimeric RAF.

UR - http://www.scopus.com/inward/record.url?scp=84942327873&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2015.08.006

DO - 10.1016/j.ccell.2015.08.006

M3 - Short survey

C2 - 26373275

AN - SCOPUS:84942327873

SN - 1535-6108

VL - 28

SP - 279

EP - 281

JO - Cancer Cell

JF - Cancer Cell

IS - 3

ER -

Path Forward for RAF Therapies: Inhibition of Monomers and Dimers

Abstract

Access to Document

Fingerprint

Cite this